Navigation Links
bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
Date:10/6/2009

SAN DIEGO, Oct. 6 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that the company has signed a two-year agreement with Lab21 to commercialize the bioTheranostics THEROS CancerTYPE ID molecular cancer classifier in the United Kingdom (UK), Ireland and Middle East countries. The agreement is effective immediately.

Under the terms of the agreement, UK-based Lab21 will market the THEROS CancerTYPE ID (CTID) molecular cancer classifier, while bioTheranostics will perform all sample testing in their CLIA-certified, CAP-accredited laboratory in San Diego, California.

The CTID assay is a 92-gene molecular cancer classifier that identifies 39 different types of tumors and 64 sub-types. It is particularly useful for oncologists and pathologists managing metastatic cancer patients whose primary tumor site (e.g., breast, lung, pancreas) is either "uncertain" or "unknown" following assessment with conventional diagnostics. The results of the CTID assay can guide physicians in selecting optimal therapies for these individuals and potentially improve treatment outcomes. Each year in the UK alone, more than 10,000 people are diagnosed with a cancer of unknown primary origin (aka CUP), and far more patients struggle with a differential diagnosis (i.e., two or more diagnostic options), each of which may lead to a different treatment path.

"We recognize a tremendous need globally for new technologies that will help physicians more quickly and accurately diagnose poorly differentiated and undifferentiated tumors, so that they can determine the optimal therapy for each patient," said Richard Ding, bioTheranostics chief executive officer. "Given Lab21's infrastructure and unique commercial expertise in personalized medicine, we know they are the right partner to deliver the THEROS CancerTYPE ID to doctors and patients in the specified countries."

"The partnership with Lab21 represents the successful transition to our second generation molecular cancer classification technology in Europe. This RT-PCR based test will replace our micro-array based assay, which was licensed to Agendia in Europe," said Ding. "Now through Lab 21, oncologists and pathologists in the specified countries can benefit from the new technology just as their American counterparts."

About bioTheranostics

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in genomic profiling and proprietary algorithms, bioTheranostics provides innovative tests to the oncology community that help drive personalized treatment. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: THEROS CancerTYPE ID(®), a molecular cancer classifier particularly helpful for patients diagnosed with metastatic cancer with their tumor origin either as uncertain or unknown or patients with their cancer origin not confirmable through conventional diagnostics; and the THEROS Breast Cancer Index(®), which refines and improves risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. More information is available at www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached euro 1.111 billion with 84% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agro-food, pharmaceutical and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

About Lab21 Limited

Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies. The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalized medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease. The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 international countries and is focused on infectious diseases for the blood-banking market. More information is available at www.lab21.com.

    Contact:  Media Relations
    Michele Parisi
    925/429-1850
    mparisi@biocommnetwork.com

    Investor Relations
    David Dai
    317/331-6185
    david.dai@biotheranostics.com

SOURCE bioTheranostics


'/>"/>
SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. One Source Industries Announces Promotion
2. The Symphony Guild Announces Artist Lineup for 2009 Event
3. Hanger Orthopedic Group, Inc. Announces Third Quarter 2009 Earnings Release Conference Call
4. China-Biotics, Inc. Announces Closing of Public Offering of Common Stock
5. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
6. Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services
7. Arcxis Biotechnologies Announces Release of First Commercial Product for Molecular Analysis
8. The Pennsylvania Breast Cancer Coalition Announces Request for Applications for Income Tax Check-Off Research Grants
9. NIDDK announces availability of more current kidney disease data
10. APWU Health Plan Announces New Benefits and Premiums for 2010
11. Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College ... academic programs. , Answering to the increasing demand for curricular specializations, the Certificate ... and environmental and land use law. ,  , “The demand for lawyers with ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: